The University of Chicago Header Logo

Connection

Koen Van Besien to Janus Kinase 1

Back to Details
This is a "connection" page, showing publications Koen Van Besien has written about Janus Kinase 1.
Koen Van Besien
Connection Strength
0.041
Janus Kinase 1
  1. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.